Business
MedX Announces $2,700,000 Initial Closing of Non-Brokered Private Placement of Series IV Convertible Loan Notes
MedX Health Corp. (“ MedX ” or the “ Company ”) (TSX-V: MDX...
About this update from Medx Health Corp.
[{"type":"text","content":"MedX Announces $2,700,000 Initial Closing of Non-Brokered Private Placement of Series IV Convertible Loan Notes\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n \n\n\n\n MedX Health Corp. (“\n \n MedX\n \n ” or the “\n \n Company\n \n ”) (TSX-V:\n \n MDX)\n \n is pleased to announce that, further to its Press Release dated February 2, 2026, it has surpassed the Minimum Subscription and closed on an Initial Closing of $2,700,000 of the non-brokered Private Placement to accredited investors. The Private Placement is for up to $5,000,000 by issuance of up to 100 Convertible Loan Notes, each with a face value of $50,000 (“\n \n Series IV Notes\n \n ”). The Series IV Notes will bear interest at 6% per year, payable Quarterly, and will mature on December 31, 2028 (the “\n \n Maturity Date\n \n ”). The Series IV Notes may be converted, at the option of the Holder, into units at $0.10 per unit (“\n \n Unit\n \n ”) at any time until the Maturity Date. Each Unit will be comprised of One (1) fully paid Common Share and One-half (1/2) of a Share Purchase Warrant. Each whole Share Purchase Warrant will be exercisable to purchase One (1) further Common Share at the price of $0.125, exercisable for a period expiring on the Maturity Date.\n \n\n Closing of the balance of Placement will be subject to receipt of subscriptions and a number of other conditions, including without limitation the receipt of all relevant regulatory and Stock Exchange approvals or acceptances. Holders of Series I Convertible Loan Notes (“\n \n Series I Notes\n \n ”) who wish to do so, will be able to surrender their Series I Notes by way of subscription for Series IV Notes. It is anticipated that, subject to compliance with relevant regulatory provisions, certain Insiders will participate in this Placement, in which case the Company will rely on exemptions from formal valuation and minority shareholder approval requirements set out in\n \n Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions.\n \n\n\n Qualified agents will receive a cash commission equal to 6% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s) and agent’s warrants (“\n \n ...